



New Horizons in Ovarian Cancer

Expert Insights into the
Role of Genetic Biomarkers
in Precision Therapy



 Presented by Creative Educational Concepts, Inc. Supported through an independent educational grant from AstraZeneca.

Disclaimer

- This slide deck in its original and unaltered format is for educational purposes and is current as of the date of this presentation. All materials contained herein reflect the views of the faculty, and not those of Creative Educational Concepts, Inc. or the commercial supporter(s).
- Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for specific patient management.
- Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review or any applicable manufacturer's product information, and comparison with recommendations of other authorities.
- **Usage Rights:** This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published or distributed in print or electronic format without prior written permission from Creative Educational Concepts, Inc. Additional terms and conditions may apply.



Ursula Matulonis, MD

Director and Program Leader
Gynecologic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Learning Objectives

- Review the DNA damage response (DDR) pathway and its role in tumorigenesis of ovarian cancers and outline the various mutations that cause defects in this pathway.
- Explore the latest clinical recommendations on genetic testing and counseling in ovarian cancer and discuss the therapeutic implications of identifying mutations in the DDR, as well as other relevant markers of genomic instability (e.g., HRD).
- Discuss current and emerging clinical data regarding the safety and efficacy of PARP inhibitors in ovarian cancer patients.
- Assess the evolving role of OB/GYN practitioners for genetic testing/counseling in patients who are at risk for or have deficiencies in the HRR pathway and discuss multidisciplinary strategies to ensure the appropriate management of patients on PARP inhibitors.

**To receive up to 1.0 AMA PRA
Category 1 Credit™, complete the evaluation and CE form
here: <https://www.surveymonkey.com/r/YVM7WW9>**



Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners

Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Robert W. Wenham MD, MS, FACOG, FACS—has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron and Seagen. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers' bureau for ONC Live and Curio Science.

Authors/Presenters

Robert W. Wenham MD, MS, FACOG, FACS—has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron and Seagen. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers' bureau for ONC Live and Curio Science.

Ursula Matulonis, MD—has disclosed that she is a consultant for AstraZeneca, Merck, NextCure, and Novartis; and receives financial or other material support from DSMB and Symphogen.

Angeles Alvarez Secord, MD—has disclosed that she receives grant/research support from AbbVie, Astra Zeneca, Clovis, Eisai, Immutep, Merck, OncoQuest, PharmaMar, Roche/Genentech, Seagen, Tesaro/GSK, VBL Therapeutics, and National Cancer Trial Network.

Shannon N. Westin, MD, MPH—has disclosed that she is a consultant for AstraZeneca, Clovis Oncology, Eisai, Merck, Novartis, Pfizer, Roche/Genentech, Tesaro/GSK, and Zentalis; and receives grant/research support from AstraZeneca, Bayer, Bio-Path, Clovis Oncology, Cotinga Pharmaceuticals, Mereo, Novartis, Roche/Genentech, and Tesaro/GSK.

Peer Reviewer

Justine Cooper Pickarski, MS, LGC—has no relevant financial relationships to disclose in relation to the content of this activity.

E-syllabus and Questions

An electronic version of the handout and program resources are available for download at:

<https://www.ceconcepts.com/ACOG-DM-2>



Have a question for the Faculty?

Use the chat feature in Zoom to ask the faculty your questions.

Special Thanks!



Supported through independent educational grants from AstraZeneca and Merck
Presented by **Creative Educational Concepts, Inc.**